12013
-
OncoTargets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
Review
(4566) Total Article Views
Authors: Steven E McCormack, Erica D Warlick
Published Date July 2010
Volume 2010:3 Pages 157 - 165
DOI: http://dx.doi.org/10.2147/OTT.S5852
Steven E McCormack, Erica D WarlickDepartment of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
Abstract: Myelodysplastic syndromes (MDS) are a varied group of diseases leading to significant morbidity and mortality. Therapy of MDS has been difficult, with supportive cares used to ameliorate symptoms, and hematopoietic stem cell transplantation the only curative option. Agents, such as the cytidine analog azacitidine, exert an effect on DNA methyltransferase leading to a reduction in DNA methylation, a process thought to be key to the pathogenesis of MDS. Recently, azacitidine has been shown to prolong survival and improve quality of life in patients with MDS, while maintaining a favorable adverse effect profile. This review highlights the scientific rationale for the use of azacitidine in addition to its application in current clinical practice for patients with MDS.
Keywords: hypomethylation, epigenetics, myelodysplastic syndromes, azacitidine
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- ASCO 2013 Meet the Editor
We invite you to meet Prof Dr Hans-Joachim Schmoll at the Dove Medical Press booth 22102 on June 1st at 11am. Prof Dr Schmoll is the Editor-in-Chief of the journal OncoTargets and Therapy (IF 1.26).
- Have an opinion about one of our articles?
We encourage you to write a letter to the editor.
- Epigenomics in cancer management
- The bradykinin B2 receptor induces multiple cellular responses leading to the proliferation of human renal carcinoma cell lines
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
- Integrative systems of genomic risk markers for cancer and other diseases: future of predictive medicine
